References
- . Grundy SM, Cleeman JI, Merz CN, . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720–732
- . Rosamond W, Flegal K, Furie K, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 117(4):e25–e146
- . Alexander KP, Newby LK, Cannon CP, ; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007; 115(19):2549–2569
- . Ray KK, Bach RG, Cannon CP, ; PROVE IT TIMI-22 Investigators. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006; 27(19):2310–2316
- . LaRosa JC, Grundy SM, Waters DD, ; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14):1425–1435
- . Poulter NR, Dalhöf B, Sever PS, Wedel H, Collier DJ. Impact of atorvastatin on cardiovascular events in 4445 men and women aged 65 years and older: evidence from the Anglo-Scandinavian Outcomes trial-lipid-lowering arm. Stroke. 2006;37(2):695
- . Massing MW, Sueta CA, Chowdhury M, Biggs DP, Simpson RJ Jr. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol. 2001;87(5):646–649, A610
- . Nichols GA, Nag S, Chan W. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am Heart J. 2007;154(3):554–560
- . Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459–467
- . Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. http://www.cdc.gov/nchs/nhanes.htm. Accessed May 10, 2010
- . Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK; Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007; 147(1):1–9
- . Koren MJ, Feldman T, Mendes RA. Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years. Clin Cardiol. 2009;32(5):256–263
- . Tikkanen MJ, Holme I, Cater NB, . Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). Am J Cardiol. 2009;103(5):577–582
- . Chaturvedi S, Zivin J, Breazna A, ; SPARCL Investigators. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology. 2009; 72(8):688–694
- . Neil HA, DeMicco DA, Luo D, ; CARDS Study Investigators. Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006; 29(11):2378–2384
- . Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–467
- . Collier DJ, Poulter NR, Dalhof B, Sever PS, Wedel H. Impact of atorvastatin on cardiovascular events in 4445 men and women aged 65 years and older: evidence from the Anglo-Scandinavian Outcomes trial-lipid-lowering arm. Poster presented at: International Stroke Conference, February 16–18, 2006; Kissimmee, FL
- . Garvey WT, Kwon S, Zheng D, . Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52(2):453–462
- . Kuller LH, Arnold AM, Psaty BM, . 10-year follow-up of subclinical cardiovascular disease and risk of coronary heart disease in the Cardiovascular Health Study. Arch Intern Med. 2006;166(1):71–78
- . Yan AT, Yan RT, Tan M, ; Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006; 119(8):676–683
- . Maroo BP, Lavie CJ, Milani RV. Efficacy and safety of intensive statin therapy in the elderly. Am J Geriatr Cardiol. 2008;17(2):92–100
- . Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638–645
- . Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–461